Brief: Biovie Completes Enrollment In Phase 2 Sunrise-Pd Trial In Early Parkinson’S Disease
08/01/2026 13:32
Jan 8 (Reuters) - BioVie Inc BIVI.O: BIOVIE COMPLETES ENROLLMENT IN PHASE 2 SUNRISE-PD TRIAL IN EARLY PARKINSON’S DISEASE BIOVIE INC - TOPLINE RESULTS FROM SUNRISE-PD TRIAL EXPECTED IN 1H 2026 Source text: ID:nGNX93z6ZH Further company coverage: BIVI.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on BioVie
See all newsBrief: Biovie Files To Offer Up To $300 Million In Securities - SEC Filing
Brief: Option Therapeutics Files For IPO Of 2.3 Million Shares Of Common Stock - SEC Filing
Brief: Biovie Completes Enrollment In Phase 2 Sunrise-Pd Trial In Early Parkinson’S Disease
Brief: Biovie Announces Pricing Of $12 Million Public Offering
Brief: Biovie Initiates Sunrise-Pd Clinical Trial Assessing Bezisterim In Early Parkinson’S Disease With First Patient Enrolled